AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells.
about
Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscleGlucose stimulates cholesterol 7alpha-hydroxylase gene transcription in human hepatocytesAMP-activated protein kinase, stress responses and cardiovascular diseasesThe AMPK signalling pathway coordinates cell growth, autophagy and metabolismMolecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisalGeneral aspects of muscle glucose uptakeAMPK: a cellular metabolic and redox sensor. A minireviewCellular and molecular mechanisms of metformin: an overviewAAV-mediated administration of myostatin pro-peptide mutant in adult Ldlr null mice reduces diet-induced hepatosteatosis and arteriosclerosisAltered metabolism and persistent starvation behaviors caused by reduced AMPK function in DrosophilaMetformin and metabolic diseases: a focus on hepatic aspectsRole of anti-diabetic drugs as therapeutic agents in Alzheimer's diseaseShizukaol D isolated from Chloranthus japonicas inhibits AMPK-dependent lipid content in hepatic cells by inducing mitochondrial dysfunctionMiltefosine Suppresses Hepatic Steatosis by Activating AMPK Signal PathwayThe kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metforminAMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant miceTreatment of nonalcoholic fatty liver disease: role of AMPK.miR-217 regulates ethanol-induced hepatic inflammation by disrupting sirtuin 1-lipin-1 signaling.Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling.Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells.High-throughput assay for modulators of mitochondrial membrane potential identifies a novel compound with beneficial effects on db/db miceDeleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice.New Insight Into Metformin Action: Regulation of ChREBP and FOXO1 Activities in Endothelial CellsAMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity?Influence of Plantago ovata husk (dietary fiber) on the bioavailability and other pharmacokinetic parameters of metformin in diabetic rabbitsAMPK and SIRT1: a long-standing partnership?OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice.Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.Metformin limits the adipocyte tumor-promoting effect on ovarian cancer.Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinaMetformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation.AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner.B lymphocytes in human subcutaneous adipose crown-like structuresGenetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metforminInvolvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis.Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
P2860
Q22241966-13FE0601-16C8-42A8-8A3A-B530273211A7Q24336253-28AD2C44-FB93-41E9-B09C-C46069BE2960Q24610297-8266C506-BCB6-4457-9690-68609D59C61AQ24616273-7BF07B06-B521-4F49-8889-62AAC3A29B34Q26783344-3A8B4583-B994-4631-A31A-4214AE70B85AQ26991925-90A25111-3195-4019-9A5B-13F51E29FDA7Q26995682-BA7D1AA5-29FC-4AE1-A6A2-010660AA082AQ27013561-281BB934-56CB-48E6-8C3B-1ECAF82B31B9Q27309898-A425D866-7384-438D-887A-F2ABB7862B91Q27320050-AA5408DF-A111-4FFD-9130-25BA0EFC2E3EQ28082736-6CFD1502-88D2-4430-86D6-05FB704576ECQ28083039-04559A9C-137F-479D-B96F-2F3FDBC6500DQ28535328-75E36BD8-28C4-4AC4-BD8B-3FD836F3CAF2Q28554383-F70298F7-DA19-4677-9670-EE8BE35ADA29Q28590162-CBD1F2B0-C07A-479A-BCAE-3154CD6F12C7Q28591122-CB25F176-A533-4DAE-B0EF-0553499849FDQ30248230-DEEB4D4A-2697-4555-BF3F-1A901EC145ECQ30359251-0885DC49-8C5A-4739-9053-B409E500791EQ30856517-45BA126B-8385-4CC4-AEA6-B584CE5D0CD5Q33322641-B5157BB2-626A-4952-BAF0-5132E5BCCFA1Q33556580-F6CD0FCA-E17B-4450-961D-22EBF61DB78EQ33604863-54F60820-8962-4BC2-849B-1CABF53D3B46Q33631578-0A8ABA7D-3D36-40F6-A5CC-30C7FDA548B1Q33688657-3B0B3AD9-51A5-444A-B77E-0BE0DC1B1889Q33776193-868CB2CB-A71E-4716-916D-2B5F1D231467Q33783499-FE4D21D6-21B6-473C-841A-36F33CCD506EQ33919545-D87F7DAC-CFE5-44FD-9B33-F4E12D7774D3Q33943164-ABCC0E08-12FF-4E5E-AD3F-C5EC67D28E25Q33968008-1612CBBF-8EA4-4853-9AEC-ECBB01AB1CDEQ34104019-655A0CFA-9A55-4A07-AB86-0A9ACF475993Q34113009-C9BF0E6C-541E-4FBF-9767-D610950AA641Q34148357-86954282-027C-45C8-8941-A7188248CB3BQ34186447-36CD0E53-027A-4C56-81A5-0B7A0B8646C6Q34186722-24B0800A-1C42-49D0-9826-19182286A012Q34214755-81A12D2F-A04E-4C10-9654-8FBB6328829BQ34292557-11A20458-8EAD-4F80-9147-1BD556DAE02FQ34433803-2C0096A8-4EBB-4984-BAA9-3F3B5BC7CA09Q34592210-5F7AB76E-C0CC-4633-BB11-BD77EF450462Q34603754-4C5897AA-6343-4CE3-B5C7-D7D43A01AE25Q34657286-4E832E2D-27A6-4D2B-BA09-DA2A733B7792
P2860
AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
AMP-activated protein kinase i ...... n-resistant human HepG2 cells.
@en
type
label
AMP-activated protein kinase i ...... n-resistant human HepG2 cells.
@en
prefLabel
AMP-activated protein kinase i ...... n-resistant human HepG2 cells.
@en
P2093
P50
P356
P1476
AMP-activated protein kinase i ...... n-resistant human HepG2 cells.
@en
P2093
Adriana Zuccollo
Daisuke Nagata
Kenneth Walsh
Richard A Cohen
Xiuyun Hou
P304
47898-47905
P356
10.1074/JBC.M408149200
P407
P577
2004-09-14T00:00:00Z